Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Vindesine MeSH Descriptor Data 2025


MeSH Heading
Vindesine
Tree Number(s)
D03.132.436.681.827.830
D03.633.100.473.402.681.827.830
D03.633.100.496.500.500.681.827.830
Unique ID
D014751
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D014751
Scope Note
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
Entry Term(s)
Compound 112531
Desacetylvinblastine Amide
Eldisine
Enison
NSC-245467
Vindesin
Vindesine Sulfate
Pharm Action
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Registry Numbers
RSA8KO39WH
0
CPH2U7DNDY
Related Numbers
53643-48-4
59917-39-4
CPH2U7DNDY
CAS Type 1 Name
Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-
Previous Indexing
Vinblastine/analogs & derivatives (1980-1985)
Vinca Alkaloids (1973-1979)
Public MeSH Note
86
History Note
86
Date Established
1986/01/01
Date of Entry
1985/04/24
Revision Date
2020/05/27
Vindesine Preferred
NSC-245467 Narrower
Vindesine Sulfate Narrower
Compound 112531 Narrower
Eldisine Narrower
page delivered in 0.123s